+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID03717844

Registry Study for Adults with Plasma Cell Disorders Including Multiple Myeloma Tracking Patient Assessments Over Time for Research and Care Improvement

Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2025-11-20

2000

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are creating a registry of patients with plasma cell disorders PCDs, such as multiple myeloma, to collect detailed assessments over time. The study aims to understand patient care patterns and satisfaction with these assessments, and to support future research in this patient group. An optional blood sample may be collected to study a genetic aging marker called p16INK4a. Participants complete a comprehensive assessment at the start and at regular intervals afterward. This assessment covers their ability to live independently, other medical conditions, cognitive and psychological health, social support, medications, and nutrition. Researchers also review patients medical records to gather more information. During the study, patients are asked to complete questionnaires and assessments repeatedly to track changes over time. The primary outcomes include building the registry and completing these assessments over ten years. Secondary outcomes focus on patient response rates to the assessment and their satisfaction. The study is observational and involves no experimental treatments, with participation lasting up to ten years.

CONDITIONS

Brief Title

Registry for Adults With Plasma Cell Disorders (PCD's)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients have an outpatient or inpatient appointment at UNC Cancer Hospitals or affiliated clinics for evaluation and management of a plasma cell disorder.
  • Patients have a documented diagnosis of a plasma cell disorder, including conditions such as multiple myeloma, amyloidosis, Castleman's disease, POEMS syndrome, and others.
  • Age 18 years or older.
  • Must consent to participate and agree to complete assessments at baseline and follow-up.
  • Must be able to read and speak English.
Not Eligible

You will not qualify if you...

  • Physical or psychiatric illnesses or problems that, in the treating clinician's judgment, would prevent successful participation in the study.
  • No imaging or lab studies are required to determine eligibility.

Research Team

N

Nicholas Mangieri

K

Kendall Conder

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here